6 voices in 10 minutes: When do we choose SGLT2i or GLP1ag?
DOI:
https://doi.org/10.47196/diab.v54i3Sup.283Keywords:
diabetes, cardiovascular risk, drugsAbstract
6 voices in 10 minutes: Strategies to reduce cardiovascular risk in patients with diabetes mellitus
When do we choose SGLT2i or GLP1ag?
In recent years, there has been a paradigm shift in diabetes’ aims of treatment, going from glycocentricity to assessment of mortality reduction and cardiovascular risk (CVR).
Three different types of diabetes drugs have been subjected to tests for assessing CV results. Most of them were focused on high-risk CV populations and all drugs demonstrated NO risk increase by using them. Some drugs even showed significant benefits and also some unexpected benefits were found, such as renal protection.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Dirección Nacional de Derecho de Autor, Exp. N° 5.333.129. Instituto Nacional de la Propiedad Industrial, Marca «Revista de la Sociedad Argentina de Diabetes - Asociación Civil» N° de concesión 2.605.405 y N° de disposición 1.404/13.
La Revista de la SAD está licenciada bajo Licencia Creative Commons Atribución – No Comercial – Sin Obra Derivada 4.0 Internacional.
Por otra parte, la Revista SAD permite que los autores mantengan los derechos de autor sin restricciones.
